The aims of this study were to determine whether the serum levels of precursor brain-derived neurotrophic factor (proBDNF), mature BDNF (mBDNF), and matrix metalloproteinase-9 (MMP-9) are altered in patients with eating disorders (ED), including anorexia nervosa (AN) and bulimia nervosa (BN), and to explore whether those levels are associated with decision-making abilities.
Decision-making is defined as the mental process of making choices among possible alternative scenarios and is performed to achieve a specific objective or to solve a specific problem.
3 Impaired decision-making may arise from dysfunctions in other neural systems, that is, neural systems concerned with memory (e.g., dorsolateral prefrontal cortex or hippocampus), or neural systems connected to the limbic system and concerned with processing affective and emotional information (e.g., insula, amygdala, cingulate cortex). 4 The Iowa Gambling Task (IGT), which evaluates decisionmaking abilities, requires the subject to learn the rewards and punishments associated with four card decks to maximize the earning of pretend money. 5 People with ED perform poorly in this task, 6, 7 which is characterized by a tendency to yield high immediate rewards despite its long-term negative consequences. 8 Brain-derived neurotrophic factor (BDNF) is one member of the nerve growth factor family, 9 and it plays a key role in neuronal survival, maturation (differentiation), and maintenance of several neuronal systems, helping to regulate synaptic plasticity. This is because BDNF is the only neurotrophin indisputably secreted in an activity-dependent manner. 10 Indeed, activity-dependent secretion of BDNF has been shown to be important for learning and hippocampus-dependent memory in humans. 11 Similar to other neurotrophins, BDNF is initially synthesized as a precursor (proBDNF), which is subsequently cleaved to produce mature BDNF (mBDNF) by extracellular proteases, such as matrix metalloproteinase-9 (MMP-9) or plasmin. 12 As described above, both proBDNF and mBDNF play important roles in several physiological functions of neurons, and it has been reported that mBDNF in particular might be related to the pathology of psychiatric disorders. Some authors have confirmed that the levels of BDNF in patients with ED were reduced in comparison with healthy controls (HC). 13, 14 Regarding the mBDNF levels in individuals with AN as well as BN, other studies have shown that they were similar to HC. 15, 16 Thus, it is unclear whether the serum levels of BDNF are altered in patients with ED.
Several pieces of evidence show that BDNF plays an important role in brain regions that not only control eating, drinking, and bodyweight but also influence cognitive dysfunction among ED patients. 17, 18 Moreover, BDNF has been implicated in decision-making, learning, and memory. 19 Patients experiencing damage to the hippocampus and orbitofrontal cortex exhibit striking deficits in real-life decision-making. To our best knowledge, no up-to-date study has evaluated the relationship between decision-making and the serum levels of proBDNF, mBDNF, and MMP-9 in ED. The present study aimed to determine whether the serum levels of proBDNF and mBDNF were altered in patients with ED. In addition, we investigated whether decision-making abilities in ED patients are associated with the serum levels of proBDNF, mBDNF, MMP-9, and clinical variables, including pathological eating dimensions.
METHODS

Participants
All patients were outpatients who were recruited from Chiba University Hospital, Japan, and met DSM-IV criteria for ED. They included 19 AN patients (AN restrictive [n = 10] and AN binge/purging [n = 9]) and 28 BN patients. In addition, the Mini International Neuropsychiatric Interview, 20 translated into Japanese, was applied. Exclusion criteria for patients with AN and BN were a history of: brain injury, epilepsy, psychosis, or drug dependence. Twenty-two age-matched controls were recruited through local advertisements and a website from a potential pool of university students and volunteers. They were determined to have none of the followinng: family history of psychiatric conditions, history of brain injury, epilepsy, psychosis, current substance abuse or dependence, risk of suicide, mental retardation, autistic spectrum disorders, comorbid depression, and bipolar disorders. Their body mass index (BMI) levels were between 19 and 25 kg/m 2 . Prior to commencement of the study, all participants provided written informed consent after receiving a full explanation regarding the nature of the study and potential risks and benefits of participation. The study was approved by the Ethics Committee of the Graduate School of Medicine Chiba University, Chiba, Japan and performed in accordance with the Declaration of Helsinki II (World Medical Association).
Procedures
Serum samples from all participants were collected between 09.00 and 15.00 hours, and stored at −80 C until use. Serum levels of proBDNF, mBDNF, and MMP-9 were measured using human proBDNF enzyme-linked immunosorbent assay (ELISA) kits, human BDNF ELISA kits (Aviscera Bioscience, Santa Clara, CA, USA), and human MMP-9 ELISA kits (R&D Systems, Minneapolis, MN, USA), respectively. To minimize assay variance, serum levels of proBDNF, mBDNF, and MMP-9 from each subject were measured on the same day. Protocols were performed according to the manufacturer's instructions. The optical density of each well was measured using an automated microplate reader (Emax; Molecular Devices, Sunnyvale, CA, USA).
Measures
The following self-reported questionnaires were administered to all participants: the Eating Disorders Inventory-2 (EDI-2); the Maudsley ObsessiveCompulsive Inventory (MOCI); the Eating Disorder Examination Questionnaire (EDEQ); the Bulimic Investigatory Test, Edinburgh (BITE); and the Hospital Anxiety and Depression Scale (HADS) (see File S1).
Neuropsychological assessment
Iowa Gambling Task (see File S1).
Data analysis
All data were analyzed according to the intention-totreat principle. For the demographic and clinical variables, summary statistics were constructed employing frequencies and proportions for categorical data, and mean and SD for continuous variables. Demographic and clinical variables for the ED and HC groups were compared using one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test. Variables that did not follow normal distribution were log-transformed before analysis.
IGT scores were defined as the number of choices from the advantageous decks (C and D) minus the number of choices from the disadvantageous decks (A and B) for all 100 trials. This net score (decks C and D minus decks A and B) calculated for each 20-choice time block enables the assessment of learning in the task. Repeated-measures ANOVA was carried out with net scores from the five blocks (decks C and D minus decks A and B in trials 1-20, 21-40, 41- 23 in IGT score were calculated.
Pearson's correlations were used to examine the relation between IGT performance and demographical and clinical variables in the whole sample and the patient groups, respectively. All comparisons were planned and the tests were two-sided. A P-value < 0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS 21.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Participant characteristics
Demographic and clinical characteristics are summarized in Table 1 . The three groups did not differ in terms of age (P = 0.62) or education (P = 0.07). On the other hand, significant differences were obtained for BMI, duration of illness, and clinical self-report measures (EDE-Q, HADS, BITE, MOCI, and EDI-2). Tukey's post-hoc test revealed that AN and/or BN differed from HC for most of the dimensional assessments.
Serum levels of proBDNF, mBDNF, and MMP-9
One-way ANOVA revealed a significant difference for MMP-9 (P = 0.001); moreover, using Tukey's test, it was found that MMP-9 in AN was significantly lower (282.23 AE 164.14 ng/mL) than in BN (384.02 AE 147.46 ng/mL, P = 0.015) or HC (480.74 AE 203.45 ng/mL, P < 0.001) (Fig. 1c) . However, the serum levels of proBDNF and mBDNF did not differ in the three groups (Fig. 1a,b) . Among the two subtypes of AN, we observed that the serum levels of mBDNF in the binge-purging AN group (16.87 AE 4.94 ng/mL) were significantly higher than in the restricting AN group (11.34 AE 5.88 ng/mL) (Student's t-test, P = 0.42), whereas serum levels of proBDNF and MMP-9 in the restricting AN group (proBDNF: 6.26 AE 3.26 ng/mL, MMP-9: 241.81 AE 152.63 ng/mL) did not significantly differ from those in the binge-purging AN group (proBDNF: 3.75 AE 1.97 ng/mL, P = 0.06; MMP-9: 327.14 AE 173.44 ng/mL, P = 0.27). When we investigated the correlation between the levels of proBDNF and MMP-9 in patients with ED and healthy controls, a significant correlation was observed (r = 0.32, P = 0.008), but not in each group separately ( Fig. 2) .
Decision-making performances
The block net scores for the three groups over the five blocks of 20 trials each are shown in Table 2 . Repeated measures ANOVA was performed on net scores for all five blocks. Mauchly's test indicated that the assumption of sphericity had been violated (P < 0.001), and therefore, the degrees of freedom were corrected using Huynh-Feldt estimates of sphericity (ε = 0.77). There was no significant main effect of group (P = 0.80), nor a group × block interaction (P = 0.06), but there was a significant main effect of block (P < 0.001) over the IGT blocks. A post-hoc least significant difference test indicated that there were significant differences in the IGT scores of the AN and BN groups compared with the HC in the that is, performance in all ED patients was significantly better than in HC, in particular in the earlier trials. When each of the different scores was calculated, we could not find any significant differences Figure 1 . Box plots of serum levels of (a) mature brain-derived neurotrophic factor (mBDNF), (b) precursor brain-derived neurotrophic factor (proBDNF), and (c) matrix metalloproteinase-9 (MMP-9) in subjects with anorexia nervosa (AN), bulimia nervosa (BN), and healthy controls (HC). The MMP-9 levels of the AN group were significantly lower than those of the BN (P = 0.016) and HC groups (P = 0.001), but the mBDNF and proBDNF levels were not significantly different. The boxes indicate the middle 50% of the values, while the whiskers extend to the minimum and maximum values, respectively, except for outliers. (Table 2) .
Correlation analysis Association between serum levels of proBDNF, mBDNF, and MMP-9 and clinical variables
We conducted correlation analyses between clinical measures including all scores of EDE-Q, BITE, EDI-2, HADS, MOCI, and the serum levels of proBDNF, mBDNF, and MMP-9 in AN and BN, respectively. The serum level of MMP-9 was positively associated with the BITE Symptom scale only in the AN group (r = 0.64, P = 0.046) (Fig. 3) .
Association between serum levels of proBDNF, mBDNF and MMP-9 and decision-making
Analysis of associations between the serum levels of proBDNF, mBDNF, and MMP-9 and the performance of decision-making revealed positive correlations between mBDNF and the fourth block (decks C and D minus decks A and B in trials 61-80) of IGT in the BN group (r = 0.41, P = 0.040) even though it was not revealed in AN (Fig. 4a) . Similarly, in BN, positive correlations were also found between MMP-9 and the same block (decks C and D minus decks A and B in trials 61-80) (r = 0.39, P = 0.046) (Fig. 4b) . Moreover, we demonstrated partial correlation analysis for all participants, controlling for the presence of disease in the serum levels of proBDNF, mBDNF, and MMP-9 and their performances in decision-making. We not only detected positive correlation between the serum levels of mBDNF and the third block of IGT (decks C and D minus decks A and B in trials 41-60) (r = 0.28, P = 0.029), but also between the serum 
DISCUSSION
To the best of our knowledge, this is the first study to examine the serum levels of proBDNF, mBDNF, and MMP-9 in patients with ED relative to the HC group, and to investigate the correlation between proBDNF, mBDNF, and MMP-9 and decisionmaking abilities.
One of the main findings of the study was that for patients with AN, the serum level of MMP-9, but not those of proBDNF and mBDNF, was significantly lower than that of either BN or HC. According to previous reports, mBDNF levels were decreased in AN compared with HC. 13, 24 Those findings were inconsistent with our result, and the difference between studies might be due to sample characteristics showing that serum levels of mBDNF were elevated in binge-purging AN patients compared to restricting AN patients, whereas serum levels in both subtypes used in the above studies were similar. This is supported by studies using large samples of AN patients, which showed that serum levels of mBDNF in AN, including both restricting and binge-purge subtypes, were not different from those in HC. 15, 25 On the other hand, we also observed, for the first time in this study, a significant correlation between the serum level of MMP-9 and the Symptom scale of BITE, which measures the degree of symptoms present, in patients with AN.
AN is characterized by a lack of maintenance of healthy bodyweight, that is, people with AN may severely limit the amount of food they eat as a result of a psychologically disturbed body image. This may lead to nutrient deficiencies and weight loss. 26 Several studies have suggested that decreased MMP-9 serum level is related to undernutrition and bodyweight loss. 27, 28 Thus, a reduction in the MMP-9 levels of our AN samples might be due to a lack of proteins as part of overall undernutrition. Studies on polymorphism of the MMP-9 gene revealed interesting results in cardiovascular diseases, 29 and neuropsychiatric disorders, such as schizophrenia. 30 In addition, Rybakowski et al. also suggested that the MMP-9 polymorphism gene may mediate the epidemiological comorbidity of neuropsychiatric illnesses with cardiovascular diseases. 31 Bradycardia and hypotension are prevalent cardiovascular diseases in ED. 32 Among psychosocial disturbances, eating disorders have the highest mortality rate. 33 Although the major direct cause of sudden death in eating disorders is life-threatening arrhythmia, in many cases of sudden death, autopsies do not clarify the main cause. 34 In contrast, the major cardiac cause of death in the general population is ischemic heart disease and hypertensive cardiac disease. 35 High serum MMP concentration was reported in patients with acute coronary syndrome and hypertension, 31, 36 whereas our result showed that serum MMP-9 was low in ED. These results indicate that decreased MMP may cause the disorder of cardiovascular regulation in ED, and in terms of MMP, the etiology and mechanism of cardiac diseases in ED are different from those in the general population.
Interestingly, we found a significant association between the serum level of MMP-9 and the pathophysiological state (symptoms of binge-eating) of AN, although the role of MMP-9 in the pathophysiology of AN is largely unknown. One possible explanation might be found in the fact that about half of the patients with AN included in this study presented with abnormal eating behaviors, such as AN binge/ purging, one of the subtypes of AN. Regarding MMP-9 level and the involvement of diet, it has been suggested that there are effects of diet on the MMP-9 level. For instance, a high-fat diet induces increased MMP-9 levels in ischemic and non-ischemic brain tissues, 37 and fasting blood glucose is also positively correlated with MMP-9 level. 38 Thus, our finding is in agreement with the above literature. Taken together with our findings, the low MMP-9 level in AN patients might not be a trait of AN patients but rather a temporary state of starvation.
On the other hand, our result of a significant correlation between the serum levels of proBDNF and MMP-9 suggested that MMP-9 plays a role in the conversion of proBDNF to mBDNF, which in turn results in tropomyosin receptor kinase B (TrkB) activation. 39 In the current study, no significant differences in the serum levels of proBDNF, mBDNF, and MMP-9 were found between the patients with BN and HC. According to a systematic review of mBDNF in BN, 40 as for the literature on mBDNF levels in BN relative to HC, two studies were inconsistent with our results. 14, 41 The difference between our results and previous studies might be attributed to: (i) the methodology used to determine serum BDNF; (ii) the assessment of BDNF in plasma instead of serum; 14 or (iii) the sample characteristics (e.g., the entire BN sample met the criteria for binge-purging type).
14,41 However, one study was in agreement, showing that the serum levels of BDNF among BN and controls did not differ statistically. 24 Another main objective of this study was to investigate whether the decision-making abilities in ED are associated with the serum levels of proBDNF, mBDNF, and MMP-9. Our results showed that mBDNF and MMP-9 levels affect decision-making abilities as measured by the use of the IGT in BN patients, but not in AN patients; that is, significant positive correlations were obtained between the mean net scores of the trials in the fourth block (decks C and D minus decks A and B in trials 61-80) and mBDNF or MMP-9, respectively. Similar to a study with schizophrenia patients, 42 there was a relation between mBDNF and the latter phase of IGT. Another author also found a similar relation in people with obsessive-compulsive disorder. 43 It remains unclear whether the discrepancy depends on the patient's pathophysiology. In addition, there were significant correlations between the serum levels of In BN, particularly, some authors have suggested that IGT performance may be related to impulsivity 44 and reward sensitivity. 45 Both animal experiments and human studies have indicated that BDNF levels are affected by conditions that are described as disruptions in the control of impulses. 46, 47 In addition, another article also reported that the serum level of MMP-9 may be associated with impulsivity, 48 which would be consistent, though indirectly, with our findings.
On the other hand, our finding, in which IGT performance in BN was linked to serum levels of mBDNF and MMP-9, may be related to reward sensitivity. This somewhat speculative explanation is supported by the study by Chan et al. 45 They suggested that decision-making in BN was characterized by elevated, consistently altered reward sensitivity using measured IGT. Brain-imaging studies of subjects with BN have also shown increased activation in response to food reward in the orbitofrontal cortex, anterior cingulate cortex, and insula in relation to reward processing. 49 Notably, dopaminergic dysfunction in the processing of reward-related stimuli has been argued to be modulated by mBDNF. 50 In addition, decreased MMP-9 levels are specifically impaired in reward-related learning. 51 Accordingly, it has been suggested that reward sensitivity, such as palatable food intake, which is one of various factors, leads to reward-seeking and binge-eating behavior in people with BN. 52 The word 'reward' may be a term to characterize them. Our findings provide a 'new step' toward shedding light on the association between the serum levels of mBDNF, MMP-9, and decision-making abilities in ED.
There are some limitations to this study. First, the sample sizes were not large. Second, we have not assessed potential implications, as described above, such as impulsivity or reward sensitivity on decision-making, which has been associated with IGT performance and the serum levels of BDNF. Further studies should address the question of how BDNF levels are involved in both impulsive symptoms and executive functions. A longitudinal study is required to investigate changes in serum levels of BDNF in accordance with decision-making ability and recovery of symptomatology of illness.
Conclusions
In conclusion, our results suggest that the serum level of MMP-9 plays a role in the pathophysiology of AN, and the serum levels of mBDNF and MMP-9 may be associated with decision-making abilities in BN. Additional studies investigating the relation between the serum levels of proBDNF, mBDNF, and MMP-9 and executive functions, including decisionmaking in ED, are needed in order to acquire a greater comprehension of the pathophysiology of ED and to help in improving treatment for these disorders.
